Rheumatology2018-07-26T17:35:18+00:00

Our Work in Rheumatology

Targeted biologics, the recent emergence of innovative new oral therapies, and the arrival of biosimilars will continue to fuel monumental shifts in the way patients with auto-immune disorders are managed. More than ever, for both existing brands & pipeline products, future success will require a deep understanding of this complex and rapidly evolving landscape.

VIEW REPORTS OFFERED IN THIS AREA

Diseases Covered

Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Systemic Sclerosis, Systemic Lupus Erythematosus, Vasculitis (GCA, PMR, ANCA), Gout

Board of Advisors

Coming soon.

Advocacy Groups

The primary objectives of advocacy groups are to educate, advocate, collaborate, and improve the efficiency of services for individuals with rheumatology related diseases and those who are close to them.

RECENT PUBLICATIONS

Analysis of Over 1,000 Systemic Lupus Erythematosus Patients Reveals Real World Patient Populations are Not Representative of Clinical Trial Samples – July 24, 2018
>VIEW ARTICLE

Rheumatologist User Base for Eli Lilly’s Taltz in Psoriatic Arthritis (PsA) Boasts Strong Growth in Q2, While Use of Pfizer’s Xeljanz Has Remained Flat Over the Past Quarter – July 17, 2018
>VIEW ARTICLE

TNF Cycling in Psoriatic Arthritis Declines for the Second Year in a Row as Newly Approved Agents Such as Pfizer’s Xeljanz and Eli Lilly’s Taltz Claim Their Share of the Switching Population – May 30, 2018
>VIEW ARTICLE

Warning to Eli Lilly’s Olumiant (baricitinib): Entrenched First-to-Market Rheumatoid Arthritis Products are Tough to Unseat – May 10, 2018
>VIEW ARTICLE

UPCOMING CONFERENCES

ACR/ARHP Annual Meeting 2017
>LEARN MORE

HELPFUL LINKS

rheuminfo logo
acr logo